成就生命科學(納斯達克：ACHV-GET評級)和VolitionRx(紐約證券交易所代碼：VNRX-GET評級)都是小盤醫療公司，但哪一家是優勢業務？我們將根據這兩家公司的收益、估值、盈利能力、分析師建議、機構所有權、風險和股息等方面的實力進行比較。
熱門資訊> 正文
評論：VolitionRx(紐約證券交易所代碼：VNRX)和實現生命科學(納斯達克：ACHV)
2022-07-06 14:11
Achieve Life Sciences (NASDAQ:ACHV – Get Rating) and VolitionRx (NYSE:VNRX – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.
Profitability
盈利能力
Get
到達
Achieve Life Sciences
實現生命科學
alerts:
警報：
This table compares Achieve Life Sciences and VolitionRx's net margins, return on equity and return on assets.
這張表格比較了實現生命科學和VolitionRx的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Achieve Life Sciences | N/A | -104.70% | -76.33% |
| VolitionRx | -15,827.93% | -148.44% | -91.08% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 實現生命科學 | 不適用 | -104.70% | -76.33% |
| 誓言Rx | -15,827.93% | -148.44% | -91.08% |
Analyst Recommendations
分析師建議
This is a summary of current recommendations for Achieve Life Sciences and VolitionRx, as provided by MarketBeat.com.
這是MarketBeat.com提供的關於實現生命科學和VolitionRx的當前建議的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Achieve Life Sciences | 0 | 0 | 2 | 0 | 3.00 |
| VolitionRx | 0 | 0 | 1 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 實現生命科學 | 0 | 0 | 2 | 0 | 3.00 |
| 誓言Rx | 0 | 0 | 1 | 0 | 3.00 |
Achieve Life Sciences currently has a consensus price target of $25.33, indicating a potential upside of 413.86%. Given Achieve Life Sciences' higher possible upside, research analysts clearly believe Achieve Life Sciences is more favorable than VolitionRx.
實現生命科學公司目前的共識目標價為25.33美元，表明潛在上漲413.86%。考慮到實現生命科學的更高可能的上行空間，研究分析師顯然認為實現生命科學比VolitionRx更有利。
Institutional & Insider Ownership
機構與內部人持股
37.3% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 11.1% of VolitionRx shares are held by institutional investors. 1.1% of Achieve Life Sciences shares are held by company insiders. Comparatively, 16.0% of VolitionRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
實現生命科學37.3%的股份由機構投資者持有。相比之下，VolitionRx 11.1%的股份由機構投資者持有。1.1%的實現生命科學股份由公司內部人士持有。相比之下，VolitionRx 16.0%的股份由公司內部人士持有。強大的機構持股表明，大型基金管理公司、對衝基金和捐贈基金相信，一隻股票有望實現長期增長。
Valuation & Earnings
估值與收益
This table compares Achieve Life Sciences and VolitionRx's top-line revenue, earnings per share (EPS) and valuation.
這張表格比較了實現生命科學和VolitionRx的營收、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Achieve Life Sciences | N/A | N/A | -$33.15 million | ($3.80) | -1.30 |
| VolitionRx | $90,000.00 | 1,267.05 | -$26.82 million | ($0.52) | -4.08 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 實現生命科學 | 不適用 | 不適用 | -3,315萬元 | ($3.80) | -1.30 |
| 誓言Rx | $90,000.00 | 1,267.05 | -2,682萬元 | ($0.52) | -4.08 |
VolitionRx has higher revenue and earnings than Achieve Life Sciences. VolitionRx is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.
VolitionRx的收入和收益比實現生命科學更高。VolitionRx目前的市盈率低於實現生命科學，這表明它目前是兩隻股票中更負擔得起的一隻。
Risk and Volatility
風險和波動性
Achieve Life Sciences has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500.
實現生命科學的貝塔指數為1.22，這表明其股價的波動性比標準普爾500指數高22%。相比之下，VolitionRx的貝塔係數為1.7，這表明其股價的波動性比標準普爾500指數高70%。
Summary
摘要
Achieve Life Sciences beats VolitionRx on 7 of the 12 factors compared between the two stocks.
在兩隻股票的12個指標中，有7個指標超過了VolitionRx。
About Achieve Life Sciences (Get Rating)
關於實現生命科學(獲取評級)
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
實現生命科學公司是一家臨牀階段的製藥公司，在加拿大、美國和英國開發和銷售用於戒菸和尼古丁成癮的西替尼克林。該公司提供西替尼克林，這是一種植物生物鹼，與大腦中的尼古丁受體相互作用，可以減輕尼古丁戒斷症狀的嚴重程度。它與Sophma AD和布里斯托爾大學簽署了許可協議。該公司總部設在加拿大温哥華。
About VolitionRx (Get Rating)
關於VolitionRx(獲取評級)
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
VolitionRx有限公司是一家跨國表觀遺傳學公司，致力於開發血液測試，以幫助診斷全球範圍內的一系列癌症和其他疾病。它銷售檢測癌症的Nu.Q；監測免疫系統的Nu.Q Nets；用於獸醫應用的Nu.Q Vet癌症篩查測試；Nu.Q Capture捕獲和濃縮樣本以進行更準確的診斷；以及Nu.Q Discover，一種分析核小體的解決方案。該公司運營的是血液檢測技術平臺--核糖體。VolitionRx有限公司總部設在德克薩斯州奧斯汀。
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《成就生命科學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對實現生命科學和相關公司的最新新聞和分析師評級的每日簡要摘要。
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
